37.00
price down icon2.17%   -0.82
 
loading

Genmab Adr (GMAB) 最新ニュース

pulisher
Oct 14, 2026

Genmab A/S (GMAB) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 14, 2026
pulisher
Oct 13, 2026

Genmab A/S ADS (GMAB) Ticks Up 0.81% as Shares Hold Above $37Exhaustion Gap - www.dars.gov.et

Oct 13, 2026
pulisher
Oct 08, 2026

Genmab A/S ADS (GMAB) Slips 1.64% as Shares Test Key Support ZoneMutual Fund Flow - https://www.siam.in/

Oct 08, 2026
pulisher
Oct 07, 2026

Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members - The Manila Times

Oct 07, 2026
pulisher
Oct 06, 2026

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL - Zacks Investment Research

Oct 06, 2026
pulisher
Oct 06, 2026

Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research

Oct 06, 2026
pulisher
Oct 05, 2026

Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge - The Motley Fool

Oct 05, 2026
pulisher
Oct 05, 2026

Genmab stock gains 5.32 percent on Rina-S data - AD HOC NEWS

Oct 05, 2026
pulisher
Oct 05, 2026

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma - GlobeNewswire Inc.

Oct 05, 2026
pulisher
Oct 05, 2026

Genmab stock after-hours at EUR 319.90: minus 0.03 percent versus the prior close at Lang & Schwarz - AD HOC NEWS

Oct 05, 2026
pulisher
Oct 05, 2026

Genmab reports Rina-S results. Genmab stock falls 1.95 percent - AD HOC NEWS

Oct 05, 2026
pulisher
Oct 03, 2026

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer - GlobeNewswire Inc.

Oct 03, 2026
pulisher
Oct 02, 2026

Major Shareholder Announcement - GlobeNewswire Inc.

Oct 02, 2026
pulisher
Oct 01, 2026

HC Wainwright keeps Buy on Genmab stock at USD 40 target - AD HOC NEWS

Oct 01, 2026
pulisher
Sep 29, 2026

GMAB Q2 2026 Earnings: EPS Beats Consensus by 36.6% as Shares Edge HigherEarnings Surprise Report - https://www.dars.gov.et/

Sep 29, 2026
pulisher
Sep 28, 2026

Genmab stock last trades at DKK 2,282.00 on September 28, 2026 - AD HOC NEWS

Sep 28, 2026
pulisher
Sep 26, 2026

Genmab stock at DKK 2,277 on September 25, 2026, up 0.40 percent - AD HOC NEWS

Sep 26, 2026
pulisher
Sep 24, 2026

Genmab stock gains 0.8 percent ahead of the open - AD HOC NEWS

Sep 24, 2026
pulisher
Sep 24, 2026

Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewswire Inc.

Sep 24, 2026
pulisher
Sep 24, 2026

Genmab stock heads into the open after a 0.84 percent gain - AD HOC NEWS

Sep 24, 2026
pulisher
Sep 23, 2026

Genmab stock gains as Kempen raises target to DKK 3,300 - AD HOC NEWS

Sep 23, 2026
pulisher
Sep 22, 2026

Genmab stock heads into the open after a 10.80 percent year gain - AD HOC NEWS

Sep 22, 2026
pulisher
Sep 22, 2026

Genmab stock advances as Q4 readouts stay on track - AD HOC NEWS

Sep 22, 2026
pulisher
Sep 22, 2026

GMAB Q2 2026 Earnings: EPS Beats Consensus by 36.6% as Shares Edge HigherEarnings Analysis - www.dars.gov.et

Sep 22, 2026
pulisher
Sep 22, 2026

GMAB Q2 2026 Earnings: EPS Beats Consensus by 36.6% as Shares Edge HigherEarnings Cycle Outlook - dars.gov.et

Sep 22, 2026
pulisher
Sep 20, 2026

Genmab stock holds steady after first-half 2026 earnings update - AD HOC NEWS

Sep 20, 2026
pulisher
Sep 19, 2026

Genmab stock gains as petosemtamab and Q2 figures draw focus - AD HOC NEWS

Sep 19, 2026
pulisher
Sep 18, 2026

Genmab stock gains as petosemtamab Phase 3 start and strong Q2 figures support valuation - AD HOC NEWS

Sep 18, 2026
pulisher
Sep 17, 2026

Genmab stock heads into the open after a modest gain - AD HOC NEWS

Sep 17, 2026
pulisher
Sep 17, 2026

Genmab stock gains as HC Wainwright lifts Q3 earnings estimates and Phase 3 petosemtamab trial begin - AD HOC NEWS

Sep 17, 2026
pulisher
Sep 16, 2026

Genmab stock gains as HC Wainwright lifts earnings estimates and confirms Buy rating - AD HOC NEWS

Sep 16, 2026
pulisher
Sep 16, 2026

Genmab stock heads into the open after a 1.6% gain in Copenhagen - AD HOC NEWS

Sep 16, 2026
pulisher
Sep 15, 2026

Coloplast stock edges lower despite strong quarterly profit surge - AD HOC NEWS

Sep 15, 2026
pulisher
Sep 10, 2026

Genmab stock gains as capital increase and updated Articles of Association support growth plans - AD HOC NEWS

Sep 10, 2026
pulisher
Sep 09, 2026

Genmab stock gains support as Barclays lifts target after warrant-driven share issue - AD HOC NEWS

Sep 09, 2026
pulisher
Sep 08, 2026

Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.

Sep 08, 2026
pulisher
Sep 08, 2026

symbol__ Stock Quote Price and Forecast - CNN

Sep 08, 2026
pulisher
Sep 08, 2026

Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewswire Inc.

Sep 08, 2026
pulisher
Sep 08, 2026

Notice to Convene an Extraordinary General Meeting of Genmab A/S - The Manila Times

Sep 08, 2026
pulisher
Sep 07, 2026

ETFs Investing in Genmab A/S Sponsored ADR Stocks - TradingView

Sep 07, 2026
pulisher
Sep 06, 2026

Genmab stock holds steady as analysts stick to a moderate buy view - AD HOC NEWS

Sep 06, 2026
pulisher
Sep 04, 2026

Genmab A/S ADSADR Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com

Sep 04, 2026
pulisher
Sep 03, 2026

Genmab (GMAB) Q2 2026 Earnings: EPS Surges 36.6% Past EstimatesCost Structure Review - careplusvn.com

Sep 03, 2026
pulisher
Sep 03, 2026

Genmab (GMAB) Q2 2026 Earnings: EPS Surges 36.6% Past EstimatesGAAP Earnings Report - dars.gov.et

Sep 03, 2026
pulisher
Sep 03, 2026

Genmab (GMAB) Q2 2026 Earnings: EPS Surges 36.6% Past EstimatesCash Flow Report - dars.gov.et

Sep 03, 2026
pulisher
Sep 01, 2026

Genmab stock holds steady as investors await next data catalysts - AD HOC NEWS

Sep 01, 2026
pulisher
Aug 31, 2026

Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingPCR Mean Reversion - dars.gov.et

Aug 31, 2026
pulisher
Aug 31, 2026

Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingMarket Cap Weight - dars.gov.et

Aug 31, 2026
pulisher
Aug 31, 2026

Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingValue Stock Ideas - dars.gov.et

Aug 31, 2026
pulisher
Aug 31, 2026

Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingWave Truncation - dars.gov.et

Aug 31, 2026
$113.07
price down icon 0.18%
$87.71
price down icon 2.76%
$33.53
price down icon 1.50%
$96.27
price down icon 2.96%
$60.96
price up icon 2.25%
$62.23
price down icon 0.95%
大文字化:     |  ボリューム (24 時間):